• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

NSCLC Drug Market to Exceed $4 Billion Between 2010 and 2015 According to the Report 'Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC'

Posted on: Monday, 14 January 2008, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c79410) has announced the addition of Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC to their offering.

In this triple analysis report the author has analyzed three major and intertwined areas of cancer R&D, Antibody drug targets, Melanoma, and NSCLC, which are all subjects to an extensive number of innovative drug candidates. This extensive 450+ pages report compiles and analyzes in parallel the progress concerning drug development and competitive situation in Antibody drug targeting and further give an in depth analysis in two key oncology areas; Leukemia and Lymphoma. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

There are currently more than 400 antibody based drugs in development for the treatment of cancer. The author has surveyed these antibodies and identified 132 antibody drug targets, belonging to 220 antibody drugs. In all they range from preclinical development to established therapy leaders in the market place. In total more than 420 clinical trials are included in this analysis, covering more than 30 different cancer indications plus diagnosis and supportive care.

Drug targets and their associated antibodies have been analyzed by the author according to:

- 34 Different molecular functions of target

- 13 Major signaling pathways

- Cancer stem cells

- Conjugated antibodies

- Therapeutic effects: Anti-angiogenesis, Apoptosis and Protein Kinase Inhibition

- 31 Targeted cancer indications

- Availability of expression profiles of targets in human tissues, cancer tissues, established cell lines and primary cell cultures

- Antibody therapeutic companies

Chapter Titles:

1 Executive Summary

2 Methodologies

3 Table of Contents

3.1 List of Figures

3.2 List of Tables

3.3 List of Boxes

4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5 Antibody Drug Targets by Molecular Function

6 Antibody Drugs Targeting Signaling Pathways

7 Antibodies Targeting Cancer Stem Cells

8 Targets of Antibody Conjugates

9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

10 Antibody Targets and Drugs by Cancer Indications

11 Expression Profiles of Antibody Drug Targets

12 Lung cancer: An Introduction

13 Progress in Current Lung Cancer Treatment Strategies

14 Key Drug Strategies in Lung Cancer

15 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

16 Etiology and Pathophysiology of Melanoma

17 Current Melanoma Treatment Strategies

18 Key Melanoma Therapy Strategies

19 Current Melanoma Drug Development: Late Stage Pipeline

20 Current Melanoma Drug Development: Early Stage Pipeline

21 Disclaimer

22 Appendix 1: Antibody Targets by Companies

23 Appendix 2. Treatment Guide Lines*

24 Appendix 3: Selected Company Profiles

25 Appendix 4 Progress profiles on approved drugs

26 Appendix 4: Treatment Guide Lines Melanoma

27 Drug Index

28 Company Index

Summary:

The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.

Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been or are comparing different combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine).

Companies Mentioned:

- Abgenix

- Aphton

- AstraZeneca

- Bristol-Myers Squibb

- Eli Lilly

- Genentech

- Genta

- GlaxoSmithKline

- ImClone

- ISIS Pharmaceuticals

- Ligand Pharmaceuticals

- OSI Pharmaceuticals

- Pfizer

- Pharmacyclics

- Sanofi- Aventis

- Telik

For more information visit http://www.researchandmarkets.com/reports/c79410.

Source: Business Wire

More News in this Category